MVA.HIVconsvOther Names: HIVconsv vaccine vectored by modified vaccinia virus Ankara Drug Class: Therapeutic Vaccines Organization: University of Oxford Phase of Development: MVA.HIVconsv is in Phase II development as a therapeutic vaccine. (MVA.HIVconsv is also being studied for HIV prevention.)
(Compound details obtained from Treatment Action Group website,1 IrsiCaixa website,2 and ClinicalTrials.gov3)
Mechanism of Action: Therapeutic vaccine. MVA.HIVconsv is a therapeutic HIV vaccine based on a modified vaccinia virus vector.4 Therapeutic vaccines are being investigated as an immunotherapeutic approach to correcting HIV-associated immune dysfunction, such as impaired dendritic cell (DC) responses to HIV and suboptimal adaptive immune responses (including HIV-specific T cell responses).5–8 A therapeutic vaccine may potentially increase the effectiveness of ART, simplify ART regimens, or allow for periodic structured treatment interruptions. A successful therapeutic vaccine would either completely eradicate the virus or improve an individual’s immune response sufficiently to suppress viral replication without ART. In either case, a therapeutic vaccine would help to circumvent a lifetime of ART.9
The MVA.HIVconsv vaccine is composed of a recombinant modified vaccinia virus Ankara (MVA) vector, which has a limited capacity to replicate in humans.4 The MVA vector carries a transgene (HIVconsv) encoding 14 HIV-1 Gag, Pol, Vif, and Env protein fragments, representing some of the most conserved segments of the HIV-1 genome across subtypes A, B, C, and D. MVA.HIVconsv is designed to induce HIV-specific CD8 cell responses against the covered vaccine antigens.4,10,11 As a therapeutic vaccine, MVA.HIVconsv has been studied as part of a prime-boost vaccine regimen, in which a ChAdV63.HIVconsv vaccine functions as the priming component and MVA.HIVconsv functions as the boosting component.12–14 MVA.HIVconsv has also been evaluated in HIV prevention trials.3,15–17
In a recent Phase II eradication study (RIVER; NCT02336074), researchers investigated a kick and kill approach consisting of ART, the ChAdV63.HIVconsv prime and MVA.HIVconsv boost vaccines plus the latency-reversing agent vorinostat in individuals with primary HIV infection who were virologically suppressed. Although the trial demonstrated significant HIV-specific cellular immunogenicity of the vaccine regimen, the overall approach as studied was unable to reduce latent HIV reservoirs more than ART given alone.14,18
Select Clinical Trials
Study Identifiers: (1) BCN01; NCT01712425 and (2) BCN02-Romi; NCT02616874
Status: BCN01 and BCN02-Romi have both been completed.
- BCN01 was an open-label trial that evaluated the safety and immunogenicity of the ChAdV63.HIVconsv and MVA.HIVconsv vaccines in individuals with recent HIV infection who had suppressed viral load levels on ART.
- BCN02-Romi was an open-label rollover study that evaluated the impact of booster doses of MVA.HIVconsv plus the latency-reversing agent romidepsin on latent HIV reservoir size and on viral rebound following a treatment interruption of ART.
- BCN01: Participants were adults with recently diagnosed HIV infection who had initiated ART with raltegravir + tenofovir DF/emtricitabine within 1 week of diagnosis. Participants were virologically suppressed within 6 months of initiating ART and had CD4 counts >350 cells/mm3.
- BCN02-Romi: Participants had completed the BCN01 trial, had at least 3 years of virological suppression, and had CD4 counts ≥500 cells/mm3.
- BCN01: Participants continued on ART plus received an intramuscular (IM) injection of ChAdV63.HIVconsv prime vaccine, followed by an IM injection of MVA.HIVconsv boost vaccine given either 8 or 24 weeks after the prime vaccine. Unvaccinated control participants were also included in the trial.
- BCN02-Romi: Participants continued on ART and received an IM injection of MVA.HIVconsv boost vaccine, followed by 3 weekly-doses of romidepsin and then a second IM injection of MVA.HIVconsv boost vaccine. A treatment interruption of ART was initiated thereafter.12,13,19,20
- CROI , 2016: Shaping CTL immunodominance with conserved HIV vaccines after early treatment (BCN01)
- CROI, 2017: Viral control induced by HIVconsv vaccines & romidepsin in early treated individuals
Study Identifiers: RIVER; NCT02336074
Sponsor: Imperial College London
Status: This study is ongoing, but not recruiting participants.
Study Purpose: The purpose of this open-label, proof-of-concept study is to determine whether a combined approach using ART plus the ChAdV63.HIVconsv and MVA.HIVconsv vaccines plus vorinostat can lead to a greater reduction in the size of the latent HIV reservoir when compared to ART alone.
Study Population: Participants are adults who have been diagnosed with primary HIV infection within 4 weeks of enrollment.
Dosing: All participants will begin receiving a standard ART regimen including an integrase inhibitor at Week 0. Thereafter, participants who achieve an undetectable viral load will be randomized to either:
- Continue on ART
- Continue on ART and receive an IM injection of ChAdV63.HIVconsv prime vaccine, followed by an IM injection of MVA.HIVconsv boost vaccine and then 10 doses of vorinostat given every 3 days.14,21
- AIDS, 2018: RIVER research in viral eradication of HIV reservoirs: a two-arm (proof of concept) randomised Phase II trial vorinostat plus a prime boost vaccine
A Phase I trial (HIV-CORE 001; NCT01024842) evaluating the safety and immunogenicity of MVA.HIVconsv and its ability to reduce the size of the latent HIV reservoir in virologically suppressed individuals on ART was also completed.22,23
BCN01 (NCT01712425); BCN02-Romi (NCT02616874):
In the BCN01 study, the majority of participants (22/24) experienced local or systemic adverse events (AEs) after vaccination. Most of these AEs were transient and Grade 1-2 in severity. Local pain was more common with MVA.HIVconsv than with ChAdV63.HIVconsv.19
The BCN02-Romi rollover trial enrolled 13 participants who had completed the BCN01 study and evaluated additional booster doses of MVA.HIVconsv along with romidepsin. The safety profile of MVA.HIVconsv was similar to what was seen in the BCN01 study.13,20RIVER (NCT02336074):
In this Phase II study, 97% (29/30) of participants in the intervention arm (ART, ChAdV63.HIVconsv, MVA.HIVconsv, and vorinostat) experienced an AE. Seventy percent of these AEs were mild, 23% were moderate, and 3% were severe in intensity. In comparison, in the ART-only arm, 73% (22/30) of participants experienced an AE, of which 33% were mild, 20% were moderate, and 20% were severe. No intervention-related serious adverse events (SAEs) were reported.14,18,21
Drug-drug interactions associated with MVA.HIVconsv are currently unknown.
- Treatment Action Group website. Research toward a cure trials. http://www.treatmentactiongroup.org/cure/trials. Accessed October 18, 2018.
- IrsiCaixa website. Safety and immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv vaccines in individuals with documented acute/recent HIV-1 infection initiating early antiretroviral treatment | BCN01. http://www.irsicaixa.es/en/safety-and-immunogenicity-chadv63hivconsv-and-mvahivconsv-vaccines-individuals-documented. Accessed October 18, 2018.
- University of Oxford. A Phase I study to evaluate the safety and immunogenicity of simultaneous prime-boost immunisations with candidate HCV and HIV-1 vaccines, AdCh3NSmut1 / ChAdV63.HIVconsv and MVA-NSmut / MVA.HIVconsv, in healthy volunteers. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered November 6, 2014. NLM Identifier: NCT02362217. https://clinicaltrials.gov/ct2/show/NCT02362217. Accessed October 18, 2018.
- The Joint Research Centre of the European Commission. GMO Register: B/ES/12/10. MVA.HIVconsv – Summary notification information format for the release of genetically modified organisms other than higher plants in accordance with article 11 of directive 2001/18/ec; 01/12/2012. http://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-ES-12-10.pdf. Accessed October 18, 2018.
- Lederman M, Rodriguez B, Sieg S. Immunopathogenesis of HIV Infection. In: Coffey S, Volberding P, eds. HIV InSite Knowledge Base. University of California San Francisco; 2004. http://hivinsite.ucsf.edu/InSite?page=kb-00&doc=kb-02-01-04. Accessed October 18, 2018.
- Miller E, Bhardwaj N. Advances in dendritic cell immunotherapies for HIV-1 infection. Expert Opin Biol Ther. 2014;14(11):1545-1549. doi:10.1517/14712598.2014.950652
- Smith PL, Tanner H, Dalgleish A. Developments in HIV-1 immunotherapy and therapeutic vaccination. F1000Prime Rep. 2014;6:43. doi:10.12703/P6-43
- Routy J-P, Boulassel M-R, Yassine-Diab B, et al. Immunologic activity and safety of autologous HIV RNA–electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol. 2010;134(2):140. doi:10.1016/j.clim.2009.09.009
- Graziani GM, Angel JB. Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions. J Int AIDS Soc. 2015;18(1). doi:10.7448/IAS.18.1.20497
- Borthwick N, Ahmed T, Ondondo B, et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther. 2014;22(2):464-475. doi:10.1038/mt.2013.248
- Rosario M, Bridgeman A, Quakkelaar ED, et al. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. European Journal of Immunology. 2010;40(7):1973-1984. doi:10.1002/eji.201040344
- IrsiCaixa. Safety and immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv candidate HIV-1 vaccines in recently HIV-1 infected individuals with early viral suppression after initiation of antiretroviral therapy (HAART). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered October 4, 2012. NLM Identifier: NCT01712425. https://clinicaltrials.gov/ct2/show/NCT01712425. Accessed October 18, 2018.
- IrsiCaixa. An open label Phase I trial to evaluate the safety and effect of HIVconsv vaccines in combination with histone deacetylase inhibitor romidepsin on the viral rebound kinetic after treatment interruption in early treated HIV-1 infected individuals (BCN02-Romi). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered November 9, 2015. NLM Identifier: NCT02616874. https://clinicaltrials.gov/ct2/show/NCT02616874. Accessed October 18, 2018.
- Imperial College London. Research in viral eradication of HIV reservoirs. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on October 23, 2014. NLM Identifier: NCT02336074. https://www.clinicaltrials.gov/ct2/show/NCT02336074. Accessed October 18, 2018.
- University of Oxford. A randomized single-blind placebo-controlled study to evaluate the safety and immunogenicity of three candidate HIV-1 vaccines, pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv, administered in combination to healthy HIV 1 uninfected adults. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered June 24, 2010. NLM Identifier: NCT01151319. https://clinicaltrials.gov/ct2/show/NCT01151319. Accessed October 18, 2018.
- University College, London. A randomised double-blind, placebo-controlled Phase I/IIa trial to investigate the effect of depletion of serum amyloid P component (SAP) on the immune response to DNA vaccination in healthy male volunteers. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered April 29, 2013. NLM Identifier: NCT02425241. https://clinicaltrials.gov/ct2/show/NCT02425241. Accessed October 18, 2018.
- University of Oxford. A Phase I/IIa clinical trial of HIV-1 vaccines pSG2.HIVconsv DNA, MVA.HIVconsv and Ad35-GRIN in combined regimens in healthy HIV-1/2-negative adults in Nairobi. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered March 26, 2014. NLM Identifier: NCT02099994. https://clinicaltrials.gov/ct2/show/NCT02099994. Accessed October 18, 2018.
- Fidler S, Stohr W, Pace M, et al. A randomised controlled trial comparing the impact of antiretroviral therapy (ART) with a “Kick-and-Kill” approach to ART alone on HIV reservoirs in individuals with primary HIV infection (PHI); RIVER trial. Abstract presented at: International AIDS Conference; July 23-27, 2018; Amsterdam, Netherlands. Abstract TUAA0202LB. http://programme.aids2018.org/Abstract/Abstract/12977. Accessed October 18, 2018.
- Mothe B, Manzardo C, Coll P, et al. Shaping CTL immunodominance with conserved HIV vaccines after early treatment (BCN01). Poster presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 22-25, 2016; Boston, MA. Poster 320. http://www.croiconference.org/sites/default/files/posters-2016/320.pdf. Accessed October 18, 2018.
- Mothe B. Viral control induced by HIVconsv vaccines & romidepsin in early treated individuals. Webcast presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 13-16, 2017; Seattle, Washington. http://www.croiwebcasts.org/console/player/33576?mediaType=slideVideo&. Accessed October 18, 2018.
- Fidler S. RIVER research in viral eradication of HIV reservoirs: a two-arm (proof of concept) randomised Phase II trial vorinostat plus a prime boost vaccine. Slides presented at: International AIDS Conference; July 23-27, 2018; Amsterdam, Netherlands. https://programme.aids2018.org/PAGMaterial/PPT/6106_3214/RIVER%20presentation%20at%20IAS%2024.7.2018%20final%20draft.pptx. Accessed October 18, 2018.
- University of Oxford. HIV-CORE 001 - a randomised placebo-controlled study to evaluate the safety and immunogenicity of a candidate HIV-1 vaccine, MVA.HIVconsv, delivered by intramuscular needle injection to HIV-1 seropositive adult subjects receiving antiretroviral therapy (ART). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered December 1, 2009. NLM Identifier: NCT01024842. https://clinicaltrials.gov/ct2/show/NCT01024842. Accessed October 18, 2018.
- Hancock G, Morón-López S, Kopycinski J, et al. Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects. J Int AIDS Soc. 2017;20(1). doi:10.7448/IAS.20.1.21171
Last Reviewed: October 18, 2018